SunRock
SunRock Biopharma is a Spain-based preclinical biotech developing first-in-class and best-in-class therapeutic antibodies, ADCs, and bispecifics targeting CCR9 and HER3 for oncology and inflammatory bowel disease, licensing programs to pharmaceutical partners for development and commercialization.
- Company typePrivate
- Founded2014
- HeadquartersSantiago De Compostela, Spain
- Headcount1–10
- GTM typeB2B
- OfferingServices
What SunRock does
SunRock Biopharma S.L. is a privately held Spanish biotechnology company founded in 2014 and headquartered at the CSIEB Biopolo Sionlla in Santiago de Compostela. The company develops a pipeline of first-in-class and best-in-class therapeutic antibodies, antibody-drug conjugates (ADCs), and bispecific antibody formats targeting the chemokine receptor CCR9 and the receptor tyrosine kinase HER3 for oncology and inflammatory diseases. Its product portfolio includes SRB5 (anti-CCR9 monoclonal antibody with enhanced ADCC for inflammatory bowel disease), SRB123 (a CCR9-targeted ADC co-developed with Escugen Biotechnology), SRB17 (a fully human anti-HER3 IgG1 developed with the University of Stuttgart), SRB19 and SRB21 (HER3-EGFR and HER3-HER2 bispecific antibodies), SRB22/EP0017 (a HER3-TRAIL bifunctional fusion protein), SRB1, and SRB2 (CCR9-targeting antibodies for solid tumors). The company has accumulated registered patent rights covering its CCR9 and HER3 antibody platforms and has generated preclinical data demonstrating 90% tumor regression in HNSCC xenograft models and complete regression in platinum-resistant ovarian and pancreatic cancer models.
SunRock firmographics
Firmographics- Name
- SunRock
- Legal name
- SunRock Biopharma S.L.
- Website
- https://sunrockbiopharma.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- SunRock Biopharma is a Spain-based preclinical biotech developing first-in-class and best-in-class therapeutic antibodies, ADCs, and bispecifics targeting CCR9 and HER3 for oncology and inflammatory bowel disease, licensing programs to pharmaceutical partners for development and commercialization.
- Ownership category
- akta.pro rank
SunRock industry classification
Industry- Product category
- Therapeutic Antibody Development (Oncology and Inflammation Biologics R&D)
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
- akta.pro secondary industries
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Bispecific & Multispecific Antibodies (HLAAAAAF), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Gastroenterology Specialty Pharmaceuticals (HLAIACAE)
Keywords
Where SunRock is headquartered
LocationHeadquarters
- HQ city
- Santiago De Compostela
- HQ country
- Spain
- HQ region
- Europe
Offices2 records
Markets served
SunRock business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Revenue model
- Licensing Agreements: SunRock licenses its antibody programs to pharmaceutical partners after preclinical validation. Partners such as Debiopharm, Ellipses Pharma, and Chime Biologics receive development and commercialization rights in exchange for upfront payments, milestone payments, and royalties.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
SunRock product offering
Product offeringCore offering
SunRock Biopharma develops first-in-class and best-in-class therapeutic antibodies, antibody-drug conjugates (ADCs), and bispecific antibodies targeting the CCR9 and HER3 receptors for oncology and inflammatory bowel disease. The company operates an open innovation model, advancing antibody candidates through preclinical validation before licensing them to pharmaceutical partners (including Ellipses Pharma, Debiopharm, and Escugen Biotechnology) for clinical development, manufacturing, and global commercialization in exchange for upfront payments, milestones, and royalties.
Product overview
SunRock Biopharma is a Spanish biotech company developing a pipeline of first-in-class and best-in-class therapeutic antibodies, antibody-drug conjugates (ADCs), and bispecific antibodies targeting validated oncology and inflammatory disease targets. The core platform focuses on CCR9 and HER3 targets. Key products include SRB5 (anti-CCR9 for IBD via ADCC), SRB123 (CCR9-targeted ADC co-developed with Escugen), SRB17 (anti-HER3 mAb), SRB19 (HER3-EGFR bispecific, licensed to Debiopharm), SRB21 (HER3-HER2 bispecific, licensed to Debiopharm), SRB22/EP0017 (HER3-TRAIL fusion protein licensed to Ellipses Pharma), and SRB2 (anti-CCR9 for pancreatic cancer). The company operates an open innovation model, advancing candidates through preclinical stages before licensing to pharmaceutical partners for clinical development.
Differentiator
Problem solved
Functional benefit
Products and services
- SRB5 Best-in-class humanized anti-CCR9 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) activity designed for selective depletion of pathogenic CCR9+ T cells in inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis.
- SRB123 First-in-class anti-CCR9 antibody-drug conjugate (ADC) co-developed with Escugen Biotechnology using the EZWi-Fit platform, designed to selectively deliver cytotoxic payloads to CCR9+ tumor cells for the treatment of solid tumors including pancreatic, ovarian, and lung cancer.
- SRB17 Best-in-class fully human anti-HER3 IgG1 monoclonal antibody with improved affinity and dual mechanism of action, developed in collaboration with University of Stuttgart, targeting HER3-overexpressing tumors.
- SRB19 Tetravalent single-chain diabody-Fc fusion protein (HER3-EGFR bispecific antibody) outperforming cetuximab in head and neck squamous cell carcinoma models; licensed to Debiopharm for development as a HER3-EGFR bispecific ADC (Debio 2512).
- SRB21 Anti-HER3-HER2 bispecific antibody licensed to Debiopharm for development as a bispecific ADC (Debio 2512).
- SRB22 (EP0017) First-in-class fully human bifunctional HER3:TRAIL fusion protein that selectively targets HER3 and induces tumor cell death via DR4 and DR5 receptors; exclusively licensed to Ellipses Pharma for global development and commercialization in solid tumors (known at Ellipses as EP0017).
- SRB2 Humanized anti-CCR9 monoclonal antibody demonstrating efficacy in pancreatic ductal adenocarcinoma through ADCC mechanism, achieving complete tumor regression in xenograft models.
- SRB1 Anti-CCR9 antibody developed for both immune-mediated inflammatory diseases and solid tumors, with clinical data presented at ECCO 2025 for the IBD indication.
Quantifiable outcome
- SRB5 demonstrates 16x higher depletion of CCR9+ T cells compared to reference anti-CCR9 antibody in preclinical studies
- +4 more outcomes
Companies that use SunRock
Customer profileSegments3 records
Ideal customer profiles1 record
SunRock technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
SunRock partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered key and core.
- Chime BiologicskeyStrategic collaboration for manufacturing development of anti-CCR9 antibody SRB5. Chime Biologics, a leading global CDMO, provides GMP manufacturing platform to scale production and accelerate preclinical and regulatory milestones for IBD indication.
- Escugen BiotechnologycoreStrategic partnership to co-develop SRB123, a first-in-class CCR9-targeted ADC. SunRock contributes proprietary SRB1 antibody; Escugen provides EZWi-Fit® platform with stable linkers and topoisomerase I inhibitor payload for optimized efficacy and safety profile.
- DebiopharmcoreMulti-asset partnership integrating SunRock's HER2/HER3 targeting antibodies with Debiopharm's Multilink™ and AbYlink™ ADC technologies. Debiopharm secured licensing options for HER3-EGFR and HER3-HER2 bispecific ADCs including SRB19 and SRB21. Extended in January 2024 for HER3-EGFR targeting in EGFR mutated cancers.
- Ellipses PharmacoreExclusive global licensing agreement for SRB22 (HER3:TRAIL bifunctional fusion protein, later named EP0017). Ellipses received worldwide rights to develop and commercialize. SunRock continues involvement through service agreement for translational activities and receives milestone payments and royalties if out-licensed.
- University of StuttgartkeyCollaboration on SRB17 development - best-in-class fully human IgG anti-HER3 with improved affinity and dual mechanism of action. University contributed to the binding site characterization that impairs ligand-dependent and allosteric activation of HER3.
- VHIO (Vall d'Hebron Institute of Oncology)keyConsortium partner in OVERCAD project (€1.8M funding) for CCR9-targeted ADC development in ovarian cancer. Also partner in TRADBI project (€1.7M) for HER3 bispecific antibodies in solid tumors. VHIO provides tumor biomarkers expertise and clinical leadership through Dr. Ana Oaknin.
- IDIS (Health Research Institute of Santiago de Compostela)keyConsortium partner in IMPANC project (€1.8M funding) for pancreatic cancer treatment. IDIS research groups (ONCOMET, Pathological Anatomy, GITEAD) validate results in patient samples and develop biomarker characterization strategies using liquid biopsy techniques.
- CiMUS (Center for Research in Molecular Medicine and Chronic Diseases)keyAcademic partner in USC-SunRock joint unit for cancer and inflammatory disease therapies (€2.73M funding). Professor Mabel Loza coordinates the initiative. Also collaborated on SRB2 pancreatic cancer research published in Molecular Oncology.
- Debiopharm (HER3-EGFR ADC extension)coreExtended licensing agreement to develop HER3-EGFR bispecific ADCs for EGFR mutated cancers, building on initial September 2023 partnership. Uses Debiopharm's Multilink™ technology for enhanced drug-to-antibody ratio.
Scale indicators6 records
Recent moves7 records
Expansion highlights6 records
SunRock competitors and assessment
Company assessmentBroad incumbents
- Genmab: Danish antibody therapeutics pioneer (DARZALEX, DuoBody®, HexaBody® platforms). Operates in the same antibody-discovery and bispecific space as SunRock at much larger scale, with an established licensing model (multiple partnered programs with pharma) — useful as a benchmark for what a mature version of SunRock's playbook can become.
Direct peers
- Zymeworks: Clinical-stage Canadian biotech developing multifunctional and bispecific antibody therapeutics (Azymetric™, Effi-function™) — directly comparable in modality (bispecifics/ADCs) and licensing-oriented business model. Both companies build differentiated antibody platforms and license assets to larger pharma for clinical development and commercialization.
- CytomX Therapeutics: Clinical-stage US biotech developing masked Probody® antibody therapeutics and bispecifics, including HER3-targeted programs in oncology. Comparable in modality (next-generation antibodies, ADCs) and in building a partnered pipeline around a proprietary platform technology.
- Pieris Pharmaceuticals (now Palvella Therapeutics): European-originated biotech that historically developed Anticalin® protein therapeutics with a similar licensing model — multiple partnered programs with AstraZeneca, Genentech, and others, small headcount, and reliance on upfront/milestone economics. Highly comparable to SunRock's stage and business model.
- Mersana Therapeutics: Clinical-stage US biotech developing antibody-drug conjugates using proprietary payload and linker platforms (Dolasynthen, Immunosynthen). Comparable in ADC focus and in targeting validated oncology indications with platform-derived candidates.
- Macrogenics: US clinical-stage biotech developing bispecific antibodies and antibody-drug conjugates using DART® and TRIDENT® platforms, including HER3-targeted programs. Comparable in modality (bispecifics, ADCs) and oncology focus, though at a more advanced clinical stage.
- Molecular Partners: Swiss clinical-stage biotech developing DARPin® protein therapeutics with a similar asset-light model — advancing candidates through preclinical/early clinical stages and partnering with larger pharma for development. Comparable in size, European base, and licensing-driven revenue strategy.
Others
- Debiopharm: Swiss biopharmaceutical group and one of SunRock's core partners (multi-asset HER3 bispecific ADC licensing). Relevant as the licensee of SunRock's SRB19/SRB21 assets and as a comparable European biopharma that invests in differentiated antibody and ADC platforms through in-licensing.
- Ellipses Pharma: London-based clinical-stage oncology group that licensed SRB22/EP0017 from SunRock in 2022. Relevant as the lead licensee of one of SunRock's key assets and as a comparable small-cap oncology company focused on advancing partnered clinical-stage assets.
Emerging players
- Compass Therapeutics: Clinical-stage US biotech with a pipeline of bispecific antibodies (CTX-009, CTX-112, CTX-131) targeting oncology. Comparable in bispecific modality and similar stage of clinical advancement, though with a larger US-based operation.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
SunRock social profiles
Digital presenceSunRock financial estimates
Financial estimateRevenue estimate
Valuation estimate
SunRock leadership team
Management profileNumber of profiles
Profiles3 records
SunRock funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
SunRock M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about SunRock
What does SunRock do?
SunRock Biopharma develops first-in-class and best-in-class therapeutic antibodies, antibody-drug conjugates (ADCs), and bispecific antibodies targeting the CCR9 and HER3 receptors for oncology and inflammatory bowel disease. The company operates an open innovation model, advancing antibody candidates through preclinical validation before licensing them to pharmaceutical partners (including Ellipses Pharma, Debiopharm, and Escugen Biotechnology) for clinical development, manufacturing, and global commercialization in exchange for upfront payments, milestones, and royalties.
Is SunRock a public or private company?
SunRock is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was SunRock founded?
SunRock was founded in 2014. It employs 1 to 10 people.
Where is SunRock based?
SunRock is headquartered in Santiago De Compostela, Spain, in the Europe region.
How does SunRock make money?
One revenue line is on record: licensing Agreements.
Who are SunRock's main competitors?
Genmab is listed as a broad incumbent. Direct peers are Zymeworks, CytomX Therapeutics, Pieris Pharmaceuticals (now Palvella Therapeutics), Mersana Therapeutics, Macrogenics and Molecular Partners. Others are Debiopharm and Ellipses Pharma. Compass Therapeutics is listed as an emerging player.
Does SunRock have an API?
No public API is recorded for SunRock.
What industry is SunRock in?
SunRock's product category is Therapeutic Antibody Development (Oncology and Inflammation Biologics R&D). Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering). Its NAICS code is 541714 and its SIC code is 2834.